Home › Funds › Defilade Capital Management, L.P. › COGT
Defilade Capital Management, L.P. position in COGT
COGENT BIOSCIENCES INC · Health Care
Defilade Capital Management, L.P. reported holding 393,441 shares of COGT (COGENT BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$15.2M, representing 2.04% of its reported portfolio and ranking #20 among its reported holdings. Defilade Capital Management, L.P. has disclosed COGT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s COGT position evolved
Defilade Capital Management, L.P. first disclosed a stake in COGT in Q4 2025 at 568,619 shares (US$20.2M). Across 3 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 393,441 shares valued at US$15.2M — an increase of 40,851 shares quarter over quarter.. Notable position changes include a 38% trim in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 568.62K | $20.20M | New |
| Q1 2026 | 352.59K | $13.57M | Reduce |
| Q2 2026 | 393.44K | $15.23M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About COGT and 13F data
COGT (COGENT BIOSCIENCES INC) is a Health Care company. 60 other funds we track also report a position in COGT — the largest reported positions include Fairmount Funds Management LLC (US$213.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$193.7M), TCG Crossover Management, LLC (US$187.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COGT
- Fairmount Funds Management LLC 5.50M sh · $212.98M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 5.01M sh · $193.74M · Q2 2026
- TCG Crossover Management, LLC 4.85M sh · $187.87M · Q2 2026
- Kynam Capital Management, LP 3.67M sh · $141.92M · Q2 2026
- Commodore Capital LP 3.05M sh · $118.03M · Q2 2026
- Octagon Capital Advisors LP 2.35M sh · $90.94M · Q2 2026
- RTW INVESTMENTS, LP 2.31M sh · $89.36M · Q2 2026
- Deep Track Capital, LP 2.00M sh · $77.40M · Q2 2026
- Siren, L.L.C. 1.86M sh · $71.95M · Q2 2026
- Venrock Adviser, LLC 1.64M sh · $63.55M · Q2 2026
- EMERALD ADVISERS, LLC 1.60M sh · $62.05M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.28M sh · $49.56M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held COGT?
Defilade Capital Management, L.P. has disclosed COGT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in COGT?
As of Q2 2026, Defilade Capital Management, L.P. holds 393.44K shares of COGT (COGENT BIOSCIENCES INC), valued at $15.23M, representing 2.04% of its reported portfolio and ranking #20.
Has Defilade Capital Management, L.P. been buying or selling COGT?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in COGT.
Which other funds hold COGT?
Other major institutional holders of COGT include Fairmount Funds Management LLC, DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.